Risk Factors Update Summary
- Additional funding needed for product development and commercialization, raising capital may cause dilution.
- Net loss decreased from $101.9 million in 2022 to $87.3 million in 2023.
- Estimated funding required extended from the second half of 2024 to 2026.
- Gross federal tax credits increased from $12 million to $16 million as of December 31, 2023.
- Accumulated deficit increased from $219 million to $306 million as of December 31, 2023.
- Devoted significant resources to developing product candidates, raising capital, and general operations.
- Enrollment delays experienced in clinical trials, impacting manufacturing processes and advanced trials.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1680367&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.